Logo image of MNMD

MIND MEDICINE MINDMED INC (MNMD) Stock Fundamental Analysis

USA - NASDAQ:MNMD - CA60255C8850 - Common Stock

12.65 USD
+0.9 (+7.66%)
Last: 11/11/2025, 2:51:54 PM
Fundamental Rating

1

MNMD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While MNMD seems to be doing ok healthwise, there are quite some concerns on its profitability. MNMD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MNMD had negative earnings in the past year.
In the past year MNMD has reported a negative cash flow from operations.
In the past 5 years MNMD always reported negative net income.
MNMD had a negative operating cash flow in each of the past 5 years.
MNMD Yearly Net Income VS EBIT VS OCF VS FCFMNMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -70.95%, MNMD is doing worse than 69.11% of the companies in the same industry.
MNMD's Return On Equity of -128.72% is on the low side compared to the rest of the industry. MNMD is outperformed by 64.92% of its industry peers.
Industry RankSector Rank
ROA -70.95%
ROE -128.72%
ROIC N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
MNMD Yearly ROA, ROE, ROICMNMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNMD Yearly Profit, Operating, Gross MarginsMNMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for MNMD has been increased compared to 1 year ago.
MNMD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MNMD has an improved debt to assets ratio.
MNMD Yearly Shares OutstandingMNMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MNMD Yearly Total Debt VS Total AssetsMNMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 0.56, we must say that MNMD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MNMD (0.56) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.31 indicates that MNMD is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.31, MNMD perfoms like the industry average, outperforming 42.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 0.56
ROIC/WACCN/A
WACCN/A
MNMD Yearly LT Debt VS Equity VS FCFMNMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

MNMD has a Current Ratio of 3.30. This indicates that MNMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MNMD (3.30) is comparable to the rest of the industry.
A Quick Ratio of 3.30 indicates that MNMD has no problem at all paying its short term obligations.
MNMD has a Quick ratio (3.30) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 3.3
MNMD Yearly Current Assets VS Current LiabilitesMNMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.27% over the past year.
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.91%
EPS Next 2Y4.86%
EPS Next 3Y5.5%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNMD Yearly Revenue VS EstimatesMNMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
MNMD Yearly EPS VS EstimatesMNMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MNMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MNMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNMD Price Earnings VS Forward Price EarningsMNMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNMD Per share dataMNMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.86%
EPS Next 3Y5.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIND MEDICINE MINDMED INC

NASDAQ:MNMD (11/11/2025, 2:51:54 PM)

12.65

+0.9 (+7.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners55.73%
Inst Owner Change0.66%
Ins Owners1.05%
Ins Owner Change-2.56%
Market Cap962.54M
Revenue(TTM)N/A
Net Income(TTM)-168.10M
Analysts84.44
Price Target25.41 (100.87%)
Short Float %13.36%
Short Ratio6.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.53%
Min EPS beat(2)-52.55%
Max EPS beat(2)-34.51%
EPS beat(4)1
Avg EPS beat(4)-23.85%
Min EPS beat(4)-52.55%
Max EPS beat(4)27.56%
EPS beat(8)3
Avg EPS beat(8)-25.48%
EPS beat(12)5
Avg EPS beat(12)-13.29%
EPS beat(16)9
Avg EPS beat(16)-0.85%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.36%
PT rev (3m)-0.36%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)-33.08%
EPS NY rev (1m)0.42%
EPS NY rev (3m)-23.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.37
P/tB 8.7
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS1.72
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.95%
ROE -128.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 3.3
Altman-Z 0.56
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.89%
EPS Next Y12.91%
EPS Next 2Y4.86%
EPS Next 3Y5.5%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.26%
EBIT Next 3Y-12.96%
EBIT Next 5Y29.36%
FCF growth 1Y-101.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.12%
OCF growth 3YN/A
OCF growth 5YN/A

MIND MEDICINE MINDMED INC / MNMD FAQ

Can you provide the ChartMill fundamental rating for MIND MEDICINE MINDMED INC?

ChartMill assigns a fundamental rating of 1 / 10 to MNMD.


Can you provide the valuation status for MIND MEDICINE MINDMED INC?

ChartMill assigns a valuation rating of 0 / 10 to MIND MEDICINE MINDMED INC (MNMD). This can be considered as Overvalued.


How profitable is MIND MEDICINE MINDMED INC (MNMD) stock?

MIND MEDICINE MINDMED INC (MNMD) has a profitability rating of 0 / 10.


What is the expected EPS growth for MIND MEDICINE MINDMED INC (MNMD) stock?

The Earnings per Share (EPS) of MIND MEDICINE MINDMED INC (MNMD) is expected to grow by 12.91% in the next year.